8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 10, 2026·SEC
Leap Therapeutics, Inc.(LPTX)Earnings, Financials & Key Ratios
LPTX•NASDAQ
11.0× P/E·Price updated May 29, 2026
AboutLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$37M+47.8%
- Net Income$5M+107.1%
- EPS (Diluted)0.07+103.8%
- ROE5.11%+103.6%
LPTX Key Insights
Leap Therapeutics, Inc. (LPTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Shares diluted 88.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LPTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LPTX Price & Volume
Leap Therapeutics, Inc. (LPTX) stock price & volume — 10-year historical chart
Loading chart...
LPTX Growth Metrics
Leap Therapeutics, Inc. (LPTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-10.68%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM98.82%
Return on Capital
10 Years-90.07%
5 Years-90.56%
3 Years-112.05%
Last Year-37.73%
LPTX Peer Comparison
Leap Therapeutics, Inc. (LPTX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 ZYME | 1.7B | 23.14 | -21.43 | 38.87% | -126.33% | -0.25% | 0.07 | |
 ALLO | 487.74M | 2.00 | -2.30 | -100% | -56.45% | 0.26 |
Compare LPTX vs Peers
Leap Therapeutics, Inc. (LPTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LPTX Income Statement
Leap Therapeutics, Inc. (LPTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 9.68M | 10.05M | 1.5M | 0 | 0 | 0 | 0 | 209K |
Revenue Growth % | - | - | - | 3.85% | -85.08% | -100% | - | - | - | -10.68% |
Cost of Goods Sold | 48K | 49K | 4.56M | 4.93M | 0 | 0 | 427K | 0 | 0 | 20.34M |
COGS % of Revenue | - | - | 47.07% | 49.06% | - | - | - | - | - | - |
Gross Profit | -48K▲ 0% | -49K▼ 2.1% | 5.12M▲ 10557.1% | 5.12M▼ 0.1% | 1.5M▼ 70.7% | 0▼ 100.0% | -427K▲ 0% | 0▲ 100.0% | 0▲ 0% | -20.13M▲ 0% |
Gross Margin % | - | - | 52.93% | 50.94% | 100% | - | - | - | - | -9631.58% |
Gross Profit Growth % | -92% | -2.08% | 10557.14% | -0.06% | -70.71% | -100% | - | 100% | - | - |
Operating Expenses | 32.35M | 30M | 8.6M | 8.57M | 42.93M | 56.76M | 86.61M | 70.06M | 36.54M | 25.44M |
OpEx % of Revenue | - | - | 88.84% | 85.22% | 2861.73% | - | - | - | - | - |
Selling, General & Admin | 9.85M | 8.92M | 7.44M | 7.02M | 10.77M | 11.8M | 13.38M | 12.85M | 10.87M | 12.52M |
SG&A % of Revenue | - | - | 76.86% | 69.85% | 717.73% | - | - | - | - | - |
Research & Development | 22.5M | 21.07M | 1.13M | 1.43M | 32.16M | 44.97M | 73.23M | 57.21M | 25.67M | 32.01M |
R&D % of Revenue | - | - | 11.63% | 14.19% | 2144% | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 34K | 118K | 0 | 0 | 0 | 0 | 0 | 1000K |
Operating Income | -32.35M▲ 0% | -30.75M▲ 4.9% | -3.48M▲ 88.7% | -3.45M▲ 0.9% | -41.43M▼ 1102.1% | -56.76M▼ 37.0% | -87.04M▼ 53.3% | -70.06M▲ 19.5% | -36.54M▲ 47.8% | -29.97M▲ 0% |
Operating Margin % | - | - | -35.91% | -34.28% | -2761.73% | - | - | - | - | -14338.28% |
Operating Income Growth % | -17.55% | 4.95% | 88.7% | 0.86% | -1102.15% | -37.02% | -53.34% | 19.51% | 47.84% | - |
EBITDA | -32.3M | -30.7M | -3.27M | -3.24M | -41.4M | -56.75M | -86.61M | -70.05M | -36.54M | -29.72M |
EBITDA Margin % | - | - | -33.78% | -32.19% | -2759.8% | - | - | - | - | -14221.05% |
EBITDA Growth % | -17.49% | 4.96% | 89.35% | 1.04% | -1179.26% | -37.08% | -52.63% | 19.12% | 47.84% | 70.01% |
D&A (Non-Cash Add-back) | 48K | 49K | 206K | 210K | 29K | 16K | 427K | 5K | 0 | 0 |
EBIT | -29.76M | -23.1M | -3.48M | -3.44M | -40.57M | -54.4M | -81.41M | -70.06M | -36.54M | -29.72M |
Net Interest Income | 49K | 428K | 290K | 54K | -32K | 871K | 4.03M | 3.13M | 892K | 549K |
Interest Income | 170K | 447K | 313K | 93K | 9K | 925K | 4.03M | 3.13M | 916K | 574K |
Interest Expense | 121K | 19K | 23K | 39K | 41K | 54K | 0 | 0 | 24K | 25K |
Other Income/Expense | 2.47M | 7.63M | 30K | 59K | 815K | 2.31M | 5.63M | 3.09M | 46.62M | -31.33M |
Pretax Income | -29.88M▲ 0% | -23.12M▲ 22.6% | -3.45M▲ 85.1% | -3.39M▲ 1.7% | -40.61M▼ 1099.0% | -54.45M▼ 34.1% | -81.41M▼ 49.5% | -66.97M▲ 17.7% | 10.08M▲ 115.0% | -56.77M▲ 0% |
Pretax Margin % | - | - | -35.6% | -33.69% | -2707.4% | - | - | - | - | -27163.64% |
Income Tax | -157K | 20K | 0 | 0 | -24K | 147K | 0 | 585K | 5.25M | 137K |
Effective Tax Rate % | 0.53% | -0.09% | 0% | 0% | 0.06% | -0.27% | 0% | -0.87% | 52.15% | -0.24% |
Net Income | -29.73M▲ 0% | -23.14M▲ 22.2% | -3.45M▲ 85.1% | -3.39M▲ 1.7% | -40.59M▼ 1098.3% | -54.6M▼ 34.5% | -81.41M▼ 49.1% | -67.56M▲ 17.0% | 4.82M▲ 107.1% | -56.91M▲ 0% |
Net Margin % | - | - | -35.6% | -33.69% | -2705.8% | - | - | - | - | -27229.19% |
Net Income Growth % | -15.98% | 22.17% | 85.11% | 1.71% | -1098.32% | -34.52% | -49.12% | 17.02% | 107.14% | 39.4% |
Net Income (Continuing) | -29.73M | -23.14M | -3.45M | -3.39M | -40.59M | -54.6M | -81.41M | -67.56M | 4.82M | -79.58M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -32.35▲ 0% | -16.05▲ 50.4% | -14.57▲ 9.2% | -4.64▲ 68.2% | -4.73▼ 1.9% | -4.82▼ 1.9% | -3.98▲ 17.4% | -1.81▲ 54.5% | 0.07▲ 103.8% | -0.34▲ 0% |
EPS Growth % | -18.54% | 50.39% | 9.22% | 68.15% | -1.94% | -1.9% | 17.43% | 54.52% | 103.77% | 98.82% |
EPS (Basic) | -32.45 | -16.36 | -14.57 | -4.64 | -4.73 | -4.82 | -3.98 | -1.81 | 0.07 | - |
Diluted Shares Outstanding | 918.86K | 1.44M | 2.26M | 5.93M | 8.58M | 11.32M | 20.45M | 37.55M | 70.67M | 168.1M |
Basic Shares Outstanding | 916.18K | 1.41M | 2.26M | 5.93M | 8.58M | 11.32M | 20.45M | 37.55M | 66.14M | 168.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LPTX Balance Sheet
Leap Therapeutics, Inc. (LPTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 27.66M | 17.32M | 5.51M | 67.3M | 116.87M | 53.22M | 71.6M | 48.04M | 162.08M | 81.92M |
Cash & Short-Term Investments | 25.74M | 16.28M | 2.39M | 63.83M | 114.92M | 43.76M | 70.64M | 47.25M | 14.04M | 6.69M |
Cash Only | 25.74M | 16.28M | 2.39M | 63.83M | 114.92M | 20.99M | 70.64M | 47.25M | 14.04M | 6.69M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 22.76M | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.74M | 836K | 2.04M | 2.01M | 1.19M | 1.36M | 771K | 704K | 148.01M | 74.47M |
Days Sales Outstanding | - | - | 77.07 | 73.09 | 289.32 | - | - | - | - | 97.53K |
Inventory | 0 | 0 | 645K | 980K | 0 | 1.4M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | 51.67 | 72.53 | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 58K | 59K | 0 | 6.26M | 183K | 86K | 40K | 768K |
Total Non-Current Assets | 1.4M | 1.75M | 3.19M | 3.11M | 1.04M | 4.88M | 1.23M | 1.08M | 1.1M | 5.46M |
Property, Plant & Equipment | 135K | 86K | 2.74M | 2.73M | 495K | 371K | 262K | 262K | 38K | 38K |
Fixed Asset Turnover | - | - | 3.54x | 3.69x | 3.03x | - | - | - | - | 0.01x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 138K | 130K | 0 | 25K | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 150K | 0 | 0 | 150K | 5.21M |
Other Non-Current Assets | 1.11M | 1.54M | 318K | 258K | 383K | 4.33M | 966K | 823K | 913K | 418K |
Total Assets | 29.06M▲ 0% | 19.07M▼ 34.4% | 8.7M▼ 54.4% | 70.42M▲ 709.5% | 117.91M▲ 67.4% | 58.09M▼ 50.7% | 72.83M▲ 25.4% | 49.12M▼ 32.5% | 163.18M▲ 232.2% | 87.38M▲ 0% |
Asset Turnover | - | - | 1.11x | 0.14x | 0.01x | - | - | - | - | 0.00x |
Asset Growth % | 350.09% | -34.37% | -54.39% | 709.47% | 67.45% | -50.73% | 25.36% | -32.55% | 232.18% | 641.14% |
Total Current Liabilities | 6.08M | 6.45M | 1.57M | 1.8M | 9.99M | 3.12M | 12.68M | 14.08M | 4.56M | 3M |
Accounts Payable | 2.62M | 3.58M | 654K | 730K | 4.19M | 1.54M | 6.46M | 4.74M | 1.98M | 516K |
Days Payables Outstanding | 19.94K | 26.66K | 52.39 | 54.02 | - | - | 5.53K | - | - | 102.22 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38K | 38K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 8K | 2.78M | 0 | 2.07M | 1.97M |
Current Ratio | 4.55x | 2.69x | 3.50x | 37.37x | 11.70x | 17.07x | 5.64x | 3.41x | 35.56x | 27.28x |
Quick Ratio | 4.55x | 2.69x | 3.09x | 36.83x | 11.70x | 16.62x | 5.64x | 3.41x | 35.56x | 27.28x |
Cash Conversion Cycle | - | - | 76.35 | 91.59 | - | - | - | - | - | 97.43K |
Total Non-Current Liabilities | 11.86M | 3.45M | 1.4M | 1.21M | 37K | 331K | 0 | 0 | 5.12M | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 769K | 524K | 37K | 256K | 0 | 0 | 0 | 971K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.12M | 5.12M |
Other Non-Current Liabilities | 11.86M | 3.45M | 632K | 685K | 0 | 75K | 0 | 0 | 0 | 0 |
Total Liabilities | 17.95M | 9.9M | 2.98M | 3.01M | 10.02M | 3.45M | 12.68M | 14.08M | 9.68M | 3M |
Total Debt | 0 | 0 | 1M | 776K | 469K | 524K | 262K | 266K | 38K | 38K |
Net Debt | -25.74M | -16.28M | -1.39M | -63.05M | -114.45M | -20.47M | -70.38M | -46.98M | -14M | -6.65M |
Debt / Equity | - | - | 0.18x | 0.01x | 0.00x | 0.01x | 0.00x | 0.01x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.22x |
Interest Coverage | -245.98x | -1215.74x | -151.13x | -88.13x | -989.51x | -1007.31x | - | - | -1522.50x | -1188.88x |
Total Equity | 11.12M▲ 0% | 9.18M▼ 17.5% | 5.72M▼ 37.6% | 67.41M▲ 1077.8% | 107.89M▲ 60.1% | 54.64M▼ 49.4% | 60.14M▲ 10.1% | 35.05M▼ 41.7% | 153.51M▲ 338.0% | 84.38M▲ 0% |
Equity Growth % | 111.09% | -17.47% | -37.62% | 1077.81% | 60.06% | -49.35% | 10.06% | -41.72% | 337.99% | 939.32% |
Book Value per Share | 12.10 | 6.37 | 2.53 | 11.36 | 12.57 | 4.83 | 2.94 | 0.93 | 2.17 | 0.50 |
Total Shareholders' Equity | 11.12M | 9.18M | 5.72M | 67.41M | 107.89M | 54.64M | 60.14M | 35.05M | 153.51M | 84.38M |
Common Stock | 12K | 15K | 69K | 142K | 88K | 142K | 26K | 38K | 84K | 94K |
Retained Earnings | -130.4M | -153.53M | -87.94M | -91.33M | -263.57M | -105.93M | -399.58M | -467.37M | -462.55M | -539.72M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -268K | 302K | 0 | 0 | -267K | 0 | 106K | -120K | -95K | -86K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LPTX Cash Flow Statement
Leap Therapeutics, Inc. (LPTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -22.14M | -26.03M | -26.9M | -25.96M | -35.16M | -49.04M | -43.75M | -60.3M | -43.9M | -40.83M |
Operating CF Margin % | - | - | -277.91% | -258.2% | -2343.8% | - | - | - | - | - |
Operating CF Growth % | 12.63% | -17.6% | -3.34% | 3.51% | -35.44% | -39.5% | 10.79% | -37.82% | 27.19% | 123.24% |
Net Income | -29.73M | -23.14M | -32.9M | -27.51M | -40.59M | -54.6M | -81.41M | -67.56M | 4.82M | -56.91M |
Depreciation & Amortization | 48K | 49K | 47K | 34K | 29K | 16K | 15K | 5K | 0 | 775K |
Stock-Based Compensation | 5.6M | 3.47M | 3.89M | 2.62M | 3.48M | 5.18M | 5.13M | 5.5M | 4.9M | 9.67M |
Deferred Taxes | -158K | 20K | 0 | 0 | 379K | 0 | 0 | 0 | 5.12M | -5.12M |
Other Non-Cash Items | -194K | -7.3M | 729K | -104K | 527K | 1.01M | 30.01M | 457K | -50.19M | 123.1M |
Working Capital Changes | 2.29M | 871K | 1.33M | -990K | 1.01M | -651K | 2.51M | 1.29M | -8.56M | -1.97M |
Change in Receivables | 1.46M | 780K | 643K | 117K | -1.16M | -1.01M | 1.3M | 0 | 149K | 42K |
Change in Inventory | 0 | 0 | 0 | 0 | 1.16M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.09M | 368K | 0 | 0 | 3.9M | 0 | 712K | 902K | -10.42M | -5.36M |
Cash from Investing | -64K | 0 | -85K | 25K | 0 | 0 | 48.97M | 0 | -97M | -92.01M |
Capital Expenditures | -64K | 0 | -100K | 0 | 0 | 0 | 0 | 0 | -97M | -102.99M |
CapEx % of Revenue | - | - | 1.03% | - | - | - | - | - | - | 49278.47% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 50.36M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -64K | 0 | 15K | 25K | 0 | 0 | -1.39M | 0 | 0 | 15.98M |
Cash from Financing | 47.76M | 15.91M | 14.82M | 74M | 98.03M | -210K | -30K | 37.18M | 107.65M | 113.12M |
Debt Issued (Net) | 750K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -440K | -437K |
Equity Issued (Net) | 49.16M | 15.03M | 15.25M | 75.5M | 97.22M | 0 | -29K | 40M | 108.09M | 113.18M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -1K | 0 | 0 | 0 |
Other Financing | -2.15M | 872K | -437K | -1.51M | 813K | -210K | -1K | -2.81M | 0 | 376K |
Net Change in Cash | 24.94M▲ 0% | -9.45M▼ 137.9% | -12.39M▼ 31.1% | 48.18M▲ 488.8% | 62.84M▲ 30.4% | -49.42M▼ 178.6% | 5.14M▲ 110.4% | -23.39M▼ 554.9% | -33.21M▼ 42.0% | -19.67M▲ 0% |
Free Cash Flow | -22.2M▲ 0% | -26.03M▼ 17.3% | -27M▼ 3.7% | -25.96M▲ 3.9% | -35.16M▼ 35.4% | -49.04M▼ 39.5% | -43.75M▲ 10.8% | -60.3M▼ 37.8% | -43.9M▲ 27.2% | -79.65M▲ 0% |
FCF Margin % | - | - | -278.95% | -258.2% | -2343.8% | - | - | - | - | -38108.13% |
FCF Growth % | 12.87% | -17.26% | -3.72% | 3.87% | -35.44% | -39.5% | 10.79% | -37.82% | 27.19% | -34.39% |
FCF per Share | -24.16 | -18.06 | -11.96 | -4.38 | -4.10 | -4.33 | -2.14 | -1.61 | -0.62 | -0.47 |
FCF Conversion (FCF/Net Income) | 0.74x | 1.13x | 7.81x | 7.66x | 0.87x | 0.90x | 0.54x | 0.89x | -9.10x | 1.40x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LPTX Key Ratios
Leap Therapeutics, Inc. (LPTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -267.4% | -228.05% | -46.26% | -9.26% | -46.31% | -67.18% | -141.86% | -141.94% | 5.11% | -46.86% |
Return on Invested Capital (ROIC) | - | - | - | -59.48% | - | -308.35% | -545.53% | - | -42.96% | -21.22% |
Gross Margin | - | - | 52.93% | 50.94% | 100% | - | - | - | - | -9631.58% |
Net Margin | - | - | -35.6% | -33.69% | -2705.8% | - | - | - | - | -27229.19% |
Debt / Equity | - | - | 0.18x | 0.01x | 0.00x | 0.01x | 0.00x | 0.01x | 0.00x | 0.00x |
Interest Coverage | -245.98x | -1215.74x | -151.13x | -88.13x | -989.51x | -1007.31x | - | - | -1522.50x | -1188.88x |
FCF Conversion | 0.74x | 1.13x | 7.81x | 7.66x | 0.87x | 0.90x | 0.54x | 0.89x | -9.10x | 1.40x |
Revenue Growth | - | - | - | 3.85% | -85.08% | -100% | - | - | - | -10.68% |
Related:LPTX Dividend History·LPTX Revenue History·LPTX Price History·LPTX P/E History·LPTX Financial Ratios·LPTX Institutional Holders
LPTX SEC Filings & Documents
Leap Therapeutics, Inc. (LPTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
LPTX Frequently Asked Questions
Leap Therapeutics, Inc. (LPTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Leap Therapeutics, Inc. (LPTX) reported $0.2M in revenue for fiscal year 2025.
Leap Therapeutics, Inc. (LPTX) grew revenue by 0.0% over the past year. Growth has been modest.
Leap Therapeutics, Inc. (LPTX) reported a net loss of $56.9M for fiscal year 2025.
Dividend & Returns
Leap Therapeutics, Inc. (LPTX) has a return on equity (ROE) of 5.1%. This is below average, suggesting room for improvement.
Leap Therapeutics, Inc. (LPTX) had negative free cash flow of $79.6M in fiscal year 2025, likely due to heavy capital investments.